Evidence map›Paper›PMID 24828196›Full record

ArticleJournal of the American Chemical Society2014

The nitric oxide reductase mechanism of a flavo-diiron protein: identification of active-site intermediates and products.

Jonathan D Caranto, Andrew Weitz, Michael P Hendrich, Donald M Kurtz

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the American Chemical Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 78 citations in OpenAlex.

  1. Review
  2. Article
  3. Hydroxo-bridged active site of flavodiiron NO reductase revealed by NRVS and DFT.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  4. Article
  5. Nitrate-Nitrite Interplay in the Nitrogen Biocycle.Molecules (Basel, Switzerland) · 2025
    Review
  6. Article
  7. Article
  8. Synthesis and Structural Characterization of a Non-Heme Iron Hyponitrite Complex.Angewandte Chemie (International ed. in English) · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. What Is the Right Level of Activation of a High-Spin {FeNO}Journal of the American Chemical Society · 2022
    Article
  13. A Nonheme Mononuclear {FeNO}Angewandte Chemie (International ed. in English) · 2021
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Mononuclear, Nonheme, High-Spin {FeNO}Inorganic chemistry · 2019
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jonathan D CarantoDepartment of Chemistry, University of Texas at San Antonio , San Antonio, Texas 78249, United States.
Andrew Weitz
Michael P Hendrich
Donald M Kurtz
Carnegie Mellon University · USThe University of Texas at San Antonio · US

Funding

UTSA RISE Research Training ProgramR25GM060655 · NIGMS · UNIVERSITY OF TEXAS SAN ANTONIO · PI BAREA-RODRIGUEZ, EDWIN J · 2000 to 2022
$21.6M
Kurtz NIHR01GM040388 · NIGMS · UNIVERSITY OF TEXAS SAN ANTONIO · PI KURTZ, DONALD M. · 1988 to 2014
$4.2M
EPR and Mossbauer Characterization of Mn and Fe Proteins, Models, IntermediatesR01GM077387 · NIGMS · CARNEGIE-MELLON UNIVERSITY · PI HENDRICH, MICHAEL P · 2006 to 2019
$2.9M
NIGMS NIH HHS GM040388NIGMS NIH HHS GM060655NIGMS NIH HHS GM077387NIGMS NIH HHS R01 GM040388NIGMS NIH HHS R01 GM077387NIGMS NIH HHS R25 GM060655
6 · The paper itself

Abstract

The unique active site of flavo-diiron proteins (FDPs) consists of a nonheme diiron-carboxylate site proximal to a flavin mononucleotide (FMN) cofactor. FDPs serve as the terminal components for reductive scavenging of dioxygen or nitric oxide to combat oxidative or nitrosative stress in bacteria, archaea, and some protozoan parasites. Nitric oxide is reduced to nitrous oxide by the four-electron reduced (FMNH2-Fe(II)Fe(II)) active site. In order to clarify the nitric oxide reductase mechanism, we undertook a multispectroscopic presteady-state investigation, including the first Mössbauer spectroscopic characterization of diiron redox intermediates in FDPs. A new transient intermediate was detected and determined to be an antiferromagnetically coupled diferrous-dinitrosyl (S = 0, [{FeNO}(7)]2) species. This species has an exchange energy, J ≥ 40 cm(-1) (JS1 ° S2), which is consistent with a hydroxo or oxo bridge between the two irons. The results show that the nitric oxide reductase reaction proceeds through successive formation of diferrous-mononitrosyl (S = ½, Fe(II){FeNO}(7)) and the S = 0 diferrous-dinitrosyl species. In the rate-determining process, the diferrous-dinitrosyl converts to diferric (Fe(III)Fe(III)) and by inference N2O. The proximal FMNH2 then rapidly rereduces the diferric site to diferrous (Fe(II)Fe(II)), which can undergo a second 2NO → N2O turnover. This pathway is consistent with previous results on the same deflavinated and flavinated FDP, which detected N2O as a product (Hayashi Biochemistry 2010, 49, 7040). Our results do not support other proposed mechanisms, which proceed either via "super-reduction" of [{FeNO}(7)]2 by FMNH2 or through Fe(II){FeNO}(7) directly to a diferric-hyponitrite intermediate. The results indicate that an S = 0 [{FeNO}(7)}]2 complex is a proximal precursor to N-N bond formation and N-O bond cleavage to give N2O and that this conversion can occur without redox participation of the FMN cofactor.

Indexed as

Catalytic DomainFlavin MononucleotideFlavoproteinsNitric OxideNitrous OxideNonheme Iron ProteinsOxidation-ReductionOxidoreductasesSpectroscopy, MossbauerFlavin MononucleotideFlavoproteinsNitric Oxidenitric-oxide reductaseNitrous OxideNonheme Iron ProteinsOxidoreductases

Identifiers

PMID24828196
PMCPMC4063189
OpenAlexW1991330623

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.